Sonnet BioTherapeutics Holdings, Inc. Gains 63.74%
Thu, Aug 19, 2021 at 05:30 PM
Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ) soared at $1.22, a gain of 63.7%. On Wed, Aug 18, 2021, SONN:NASDAQ touched a New 2-Week Low of $0.75. The stock appeared on our News Catalysts scanner on Mon, Aug 16, 2021 at 07:49 AM in the 'INVESTOR UPDATE' category. From Wed, Aug 04, 2021, the stock recorded 20.00% Up Days and 9.09% Green Days
About Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ)
Sonnet BioTherapeutics Holdings Inc is a biotechnology company engaged in the development of biologic drugs focused on human antibody binding technology. The firm's pipeline products include SON-080 (low-dose IL-6), SON-081 (low dose IL-6), SON-1010 (IL12-FHAB), and others.
Top 10 Gainers:
- Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 63.74%
- Sonoma Pharmaceuticals, Inc. (SNOA:NASDAQ), 50.65%
- DLO (DLO:NASDAQ), 26.68%
- China Liberal Education Holdings Limited (CLEU:NASDAQ), 22.71%
- ENSC (ENSC:NASDAQ), 22.36%
- DATS (DATS:NASDAQ), 21.78%
- Macy's, Inc. (M:NYSE), 19.59%
- DNUT (DNUT:NASDAQ), 14.08%
- STVN (STVN:NYSE), 13.53%
- InVivo Therapeutics Holdings Corp. (NVIV:NASDAQ), 12.31%